Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents Awarded to FSU, Asuragen

Premium

Title: RNAi Therapeutic for the Treatment of Hepatitis C Infection

Patent Number: 8,563,529

Filed: July 26, 2012

Inventor: Hengli Tang, Florida State University

The invention, the patent's abstract states, comprises "small interfering RNAs or small hairpin RNA … that target human cyclophilin A to inhibit hepatitis C infection. Such siRNA and shRNAs may have a length of about 19 to 29 contiguous nucleotides corresponding to a specific region of human cyclophilin A cDNA from about nucleotide 155 to about nucleotide 183. ... Such siRNA and shRNAs may be formulated as naked or pharmaceutical compositions. DNA polynucleotides, plasmids, and viral or non-viral vectors are provided that encode siRNA or shRNA molecules, which may be delivered directly to cells or in combination with delivery agents, such as lipids, polymers, [and] encapsulated lipid particles, such as liposomes. Methods for treating, managing inhibiting, preventing, etc., HCV infection using such siRNA and shRNAs and compositions comprising same are also provided."


Title: Methods and Compositions Involving miRNA and miRNA Inhibitor Molecules

Patent Number: 8,563,708

Filed: Aug. 10, 2007

Lead Inventor: David Brown, Asuragen

The invention concerns "methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules," the patent's abstract states. "Moreover, the … invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more